Immunodiagnostic Systems Hldgs PLC Launch of IDS-iSYS (6868N)
August 10 2017 - 9:00AM
UK Regulatory
TIDMIDH
RNS Number : 6868N
Immunodiagnostic Systems Hldgs PLC
10 August 2017
Immunodiagnostic Systems Holdings plc.
10 August 2017
Launch of IDS-iSYS Free Testosterone assay - new assay in the
IDS fertility portfolio
Immunodiagnostic Systems Holdings plc (IDS), a specialty
solution provider to the clinical laboratory diagnostic market, has
today launched the IDS-iSYS Free Testosterone assay in the European
market. This is a fully automated CLIA assay for use with serum and
plasma samples on the IDS-iSYS Automated System.
The launch of the IDS-iSYS Free Testosterone assay is the third
product released as part of the emerging fertility (steroid
hormones) portfolio.
The IDS-iSYS Free Testosterone assay quantitatively measures a
patient's Free Testosterone level and offers clinicians an easy,
non-invasive way to diagnose and treat disorders involving the male
sex hormones (androgens). Measurement of free testosterone may
provide additional information in patients whereby the measured
total testosterone levels are low.
As the first fully automated solution, the IDS-iSYS Free
Testosterone assay is a valuable addition to the developing IDS
fertility portfolio; allowing laboratories to benefit from reduced
time to first result for measurement of patient samples.
The global market for testosterone testing is valued at around
$110 million per year.
For further information:
Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660
Regis Duval, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGUQARUPMGPU
(END) Dow Jones Newswires
August 10, 2017 09:00 ET (13:00 GMT)
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Apr 2024 to May 2024
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From May 2023 to May 2024